Sartorius Stedim Biotech Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
10,483
- Stock Symbol
-
DIM
- Investments
-
14
- Share Price
-
$250.80
- (As of Thursday Closing)
Sartorius Stedim Biotech General Information
Description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact Information
Corporate Office
- Zone Industrielle les Paluds
- Avenue de Jouques CS 91051
- 13781 Aubagne
- France
Corporate Office
- Zone Industrielle les Paluds
- Avenue de Jouques CS 91051
- 13781 Aubagne
- France
Sartorius Stedim Biotech Stock Performance
As of 19-Nov-2026, Sartorius Stedim Biotech’s stock price is $250.80. Its current market cap is $24.4B with 97.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $250.80 | $249.31 | $175.26 - $262.41 | $24.4B | 97.3M | 91.9K | $3.87 |
Sartorius Stedim Biotech Financials Summary
As of 30-Sep-2026, Sartorius Stedim Biotech has a trailing 12-month revenue of $3.56B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 25,983,244 | 26,655,690 | 21,567,642 | 28,528,719 |
| Revenue | 3,556,914 | 3,347,358 | 3,008,235 | 3,003,300 |
| EBITDA | 1,018,369 | 924,063 | 705,096 | 811,016 |
| Net Income | 376,326 | 299,598 | 189,476 | 335,768 |
| Total Assets | 9,115,919 | 9,378,157 | 8,591,378 | 8,544,852 |
| Total Debt | 2,620,036 | 3,053,187 | 2,986,025 | 4,070,082 |
Sartorius Stedim Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sartorius Stedim Biotech Patents
Sartorius Stedim Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240209411-A1 | Method for sterility testing | Pending | 26-Apr-2021 | ||
| US-10947489-B2 | Bioreactor system and method | Active | 02-Jun-2015 | ||
| US-20180187140-A1 | Bioreactor system and method | Active | 02-Jun-2015 | ||
| WO-2013160594-A1 | Sterile individual set for producing biopharmaceutical products | Inactive | 24-Apr-2012 | ||
| WO-2013102738-A1 | Container for biopharmaceutical content | Inactive | 05-Jan-2012 | C12M29/00 |
Sartorius Stedim Biotech Signals
Sartorius Stedim Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sartorius Stedim Biotech Investments & Acquisitions (14)
Sartorius Stedim Biotech’s most recent deal was a Later Stage VC with Nanotein Technologies for . The deal was made on 11-Aug-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nanotein Technologies | 11-Aug-2025 | Later Stage VC | Drug Discovery | ||
| ViroCell Biologics | 14-Aug-2024 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
| ViroCell Biologics | 15-Nov-2022 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
| Xell | 29-Jul-2021 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Novasep (Chromatography Equipment Division) | 07-Feb-2021 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Sartorius Stedim Biotech ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
18.96 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Sartorius Stedim Biotech Exits (2)
Sartorius Stedim Biotech’s most recent exit was on 14-Aug-2024 from ViroCell Biologics. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| ViroCell Biologics | 14-Aug-2024 | Completed |
|
||
| ViroCell Biologics | 15-Nov-2022 | Early Stage VC | Completed |
|
Sartorius Stedim Biotech Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sartorius Chromatography Equipment | Pompey, France | 2020 | |
| Sartorius Stedim Fmt | Aubagne, France | 2012 | |
| Xell | Schloß Holte-Stukenbrock, Germany | 2009 | |
| Sartorius Stedim Aseptics | Lourdes, France | 1994 |
Sartorius Stedim Biotech FAQs
-
When was Sartorius Stedim Biotech founded?
Sartorius Stedim Biotech was founded in 1978.
-
Where is Sartorius Stedim Biotech headquartered?
Sartorius Stedim Biotech is headquartered in Aubagne, France.
-
What is the size of Sartorius Stedim Biotech?
Sartorius Stedim Biotech has 10,483 total employees.
-
What industry is Sartorius Stedim Biotech in?
Sartorius Stedim Biotech’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Sartorius Stedim Biotech a private or public company?
Sartorius Stedim Biotech is a Public company.
-
What is Sartorius Stedim Biotech’s stock symbol?
The ticker symbol for Sartorius Stedim Biotech is DIM.
-
What is the current stock price of Sartorius Stedim Biotech?
As of 19-Nov-2026 the stock price of Sartorius Stedim Biotech is $250.80.
-
What is the current market cap of Sartorius Stedim Biotech?
The current market capitalization of Sartorius Stedim Biotech is $24.4B.
-
What is Sartorius Stedim Biotech’s current revenue?
The trailing twelve month revenue for Sartorius Stedim Biotech is $3.56B.
-
What is Sartorius Stedim Biotech’s annual earnings per share (EPS)?
Sartorius Stedim Biotech’s EPS for 12 months was $3.87.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process